“Hubungan Ekspresi Vegf Dengan Respon Kemoterapi Neoadjuvan Ifosfamide-Cisplatin Pada Kanker Serviks Stadium Ib-Iia”
DAFTAR PUSTAKA
1. GLOBOCAN 2012 (IARC), Cervical Cancer, Estimated Incidence,
mortality and prevalence Worldwide in 2012. Section of Cancer
surveillance. 2012. [Diakses tanggal 21 Desember 2016]. Tersedia di:
http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp.
2. World Health Organization (WHO). Comprehensive cervical cancer
prevention and control: a healthier future for girls and women. WHO
guidance note. 2013. Geneva: WHO Press. [Diakses tanggal 21
Desember
2016].
Tersedia
di:
http://www.who.int/immunization/hpv/learn/comprehensive_cervical_c
ancer_who_2013.pdf
3. Information Centre on HPV and Cancer (ICO-HPV Information Centre).
Human Papillomavirus and Related Diseases in Indonesia. Summary
Report. December 2016. [Diakses tanggal 24 Desember 2016].
Tersedia di http://www.hpvcentre.net/statistics/reports/XWX.pdf
4. Kementerian Kesehatan Republik Indonesia (RI). Situasi penyakit
kanker. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan
Republik Indonesia. 2015. [Diakses tanggal 24 Desember 2016].
Tersedia
di:
http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodat
in-kanker.pdf
Universitas Sumatera Utara
5. Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C.
Cervical cancer: ESMO clinical practice guidelines for diagnosis,
treatment, and follow-up. Ann Oncol. 2012;23:vii27-32.
6. Mabuchi S, Kawano M, Sasano T, Kuroda H. Management of earlystage and locally advanced cervical cancer. In: Shoupe D. Handbook
of gynecology. Switzerland:Springer. 2016. p1-9.
7. Lee S-J, Kim J-H, Yoon J-H, Lee K-H, Park D-C, Kim C-J.
Neoadjuvant Chemotherapy for Cervical Cancer: Rationale and
Evolving Data. 2013. [Diakses tanggal 20 Januari 2017]. Tersedia di:
http://www.intechopen.com/books/neoadjuvant-chemotherapyincreasing-relevance-in-cancer-management/neoadjuvantchemotherapy-for-cervical-cancer-rationale-and-evolving-data
8. Bradbury M, Founta C, Taylor W, Kucukmetin A, Naik Raj, Ang C.
Pathological risk factors and outcomes in women with stage IB2
cervical cancer treated with primary radical surgery versus
chemoradiotherapy. Int J Gynecol Cancer. 2015;25:1476-83.
9. Wang H, Zhu L, Lu W, Xu H, Yu Y,Yang Y. Clinicopathological risk
factors for recurrence after neoadjuvant chemotherapy and radical
hysterectomy in cervical cancer. World Journal of Surgical Oncology.
2013;11:301
10. McCann GA, Taege SK, Boutsicaris CE, Philips GS, Eisenhauer EL,
Fowler JM, O’Malley DM, et al. The impact of close surgical margins
after radical hysterectomy for ealy-stage cervical cancer. Gynecol
Oncol. 2013;128:44-8.
11. Moore DH. Review: Neoadjuvant chemotherapy for cervical cancer.
Expert Opin. Pharmacother. 2003;4:859-67.
12. Robova H, Rob L, Halas MJ, Pluta M, Skapa P, Strnad P, et al. Highdose density neoadjuvant chemotherapy in bulky IB cervical cancer.
Gynecologic Oncology. 2013;128:49–53.
13. Friedlander M, Kaye SB, Sullivan A, Atkinson K, Elliott P, Coppleson
M. Cervical carcinoma: a drug-responsive tumor-experience with
combined cisplatin, vinblastine, and bleomycin therapy.Gynecol Oncol.
1983;16:275-81.
Universitas Sumatera Utara
14. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant
chemotherapy plus surgery versus surgery for cervical cancer.
Cochrane Collab. 2010;1:1-25.
15. Wang Y, Wang G, Wei L-H, Wang J-L, Wang S-J, Li X-P. Neoadjuvant
chemotherapy for locally advanced cervical cancer reduces surgical
risks and lymph-vascular space involvement. Chin J Cancer. 2011;30:
645-52
16. Dasari SM, Tchounwou PB. Cisplatin in cancer therapy:molecular
mechanisms of action. Eur J Pharmacol. 2014;0:364-78.
17. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of
resistance. Oncogene. 2003:22;7265-79.
18. Page R, Takimoto. Principles of chemotherapy. In: Padzur R, Coia LR,
Hoskins WJ, Wagman LD. Cancer management: A multidisciplinary
approach. Medical, surgical, and radiation Oncology. 7th eds. New
York: The Oncology Group. 2003. p21-37.
19. Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, Lee JW, et al.
Prognostic significance of VEGF expression in patients with bulky
cervical carcinoma undergoing
20. Ye Q, Yuan HX, Chen HL. Responsiveness of neoadjuvant
chemotherapy before surgery predicts favorable prognosis for cervical
cancer patients: A meta-analysis. J Cancer Res Clin Oncol.
2013;139:1887-98.
21. Ramez N, Eskander, Tawari KS. Targeting angiogenesis in advanced
cervical cancer. Ther Adv Med Oncol. 2014;6:280-92.
22. Sakurai T, Kudo M. Signaling
angiogenesis. Oncol. 2011;81:24-9.
pathways
governing
tumor
23. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell
survival functions of vascular endothelial growth factor (VEGF). J Cell
Mol Med. 2005;9:777-94.
24. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E,
Spandidos DA. VEGF, FGF, TGFB1, and TGFBR1 mRNA expression
levels correlate with the malignant transformation of the uterine cervix.
Cancer Letters. 2005;221:105-18.
Universitas Sumatera Utara
25. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peter
WA, et al. Markers of angiogenesis in high-risk, early stage cervical
cancer: A gynecologic oncology group study. Gynecol Oncol.
2009;112:583-9.
26. Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in
recurrent cervical cancer. Oncology Letters. 2010;1:3-11.
27. European Society for Medical Oncology (ESMO). Cervical cancer.
2012.[Diakses tanggal 21 Desember 2016]. Tersedia di:
https://www.esmo.org/content/download/6675/115556/file/ENCervical-Cancer-Guide-for-Patients.pdf.
28. Morshed K, Gruszka DP, Szymanski M, Dacewicz MP. Human
papillomavirus (HPV)- Structure, epidemiology and pathogenesis.
Otolaryngol Pol. 2014;150:1-7.
29. Vet JNI, de Boer MA, van den Akker BEWM, Siregar B, Lisnawati,
Budiningsih S, et al. Prevalence of human papillomavirus in Indonesia:
a population-based study in three regions. British Journal of Cancer.
2008;99:214-8
30. Domingo EJ, Noviani R, Rushdan M, Ngelangel CA, Limpaphayom
KK, Thuan TV, Louie KS, Quinn MA. Epidemiology and prevention of
cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and
Vietnam. Vaccine. 2008;26S:M71-9.
31. Rasjidi I. Epidemiologi kanker serviks. Indonesian Journal of Cancer.
2009;3:104-6.
32. Shield TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG.
A case-control study of risk factors for invasive cervical cancer among
U.S. women exposed to oncogenic types of human Papillomavirus.
Cancer Epidemol Biomarkers Prev. 2004;13:1574-80.
33. Hinkula M, Pukkala E, Kyyronen P, Laukkanen P, Koskela P,
Paavonen J. A population-based study on the risk of cervical cancer
and cervical intraepithelial neoplasia among grand multiparous women
in Finland. British Journal of Cancer. 2004;90:1025-9.
Universitas Sumatera Utara
34. Schiffman M, Wentzensen N. Human papillomavirus (HPV) infection
and the multi-stage carcinogenesis of cervical cancer. Cancer
Epidemol Biomarkers Prev. 2013;22:553-60.
35. Gómez DT, Santos JL. Human papilloma virus infection and cervical
cancer: pathogenesis and epidemiology. In: Vilas AM. Communicating
Current Research and Educational Topics and Trends in Applied
Microbiology. 2007. p680-8.
36. Hoffman BL, Schorge JO, Schaffer JI, Halvorson LM, Bradshaw KD,
Cunningham FG. Cervical Cancer. Dalam: Williams Gynecology. Edisi
ke-3. New York: McGraw-Hill. 2016. h.769-92.
37. Yan M, Zhang YN, He JH, Sun JR, Sun XM. Influence of lymph
vascular space invasion on prognosis of patients with early-stage
cervical squamous cell carcinoma. Chinese J Cancer. 2010;29:42530.
38. Eurocytology. Cervical cytology (Up to date 2016). In: Pathogenesis of
cervical cancer. Diakses tanggal 20 Januari 2017. Terdapat di:
http://www.eurocytology.eu/en/course/969
39. Khan M, Diaz-Montes TP. Cervical cancer. In: Hurt KJ, Guile MW,
Bienstock JL, Fox HE, Wallach EE. The John Hopkins manual of
gynecology and obstetrics. 4th eds. Philadelphia: Lippincott Williams &
Wilkins. 2011. p541-58.
40. Wiebe E, Denny L, Thomas G. Cancer of the cervix uteri. Int J
Gynaecol Obstet. 2012;119S2:S100-9.
41. Kementerian Kesehatan. Pedoman nasional pelayanan kedokteran
(PNPK) : Kanker Serviks. Jakarta: Kementrian Kesehatan. 2015. h.165.
42. Vaupel P, Harrison L., Tumor hypoxia: causative factors,
compensatory mechanisms, and cellular response. Oncologist. 2004;
5:4-9.
43. Masoud. GN, Li. W., HIF-1α pathway: role, regulation and intervention
for cancer therapy. Acta Pharmaceutica Sinica B. 2015;5:378-89.
Universitas Sumatera Utara
44. Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, Zoratto F, Panici
PB, Tomao S. Angiogenesis and antiangiogenic agents in cervical
cancer. OncoTargets and Therapy. 2014;7:2237-48.
45. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor
(VEGFR) signaling in angiogenesis: A crucial target for anti- and proangiogenic therapies. Genes & Cancer. 2011;2:1097-105
46. Weis SM, Cheresh DA. Tumor Angiogenesis: molecular pathways and
therapeutic targets. Nature Medicine. 2011;17:1359-64.
47. Senger DR, Davis GE. Angiogenesis. Cold Spring Harb Perspect Biol.
2011;3:1-19.
48. Bowden DJ, Barett T. Angiogenesis imaging in neoplasia. Journal of
Clinical Imaging Science. 2011;1:1-7
49. Berek JS, Hacker NF. Biology and Genetics. Dalam: Gynecologic
Oncology. Edisi ke-6. Wolters Kluwer. 2015. h.15-16.
50. Bielenberg D. Angiogenesis signaling pathway. 2014. Diakses tanggal
10
Januari
2017.
Terdapat
di:
https://www.cellsignal.com/contents/science-pathway-researchangiogenesis-resources/angiogenesis-signaling-pathway/pathwaysangiogenesis
51. Ziyad S, Iruela-Arispe ML. Molecular mechanism
angiogenesis. Genes&Cancer. 2011;2:1085-96.
of
tumor
52. Schlieve CR, Mojica SG, Holoyda KA, Hou XG, Fowler KL, Grickscheit
TC. Vascular endothelial growth factor (VEGF) bioavaibility regulates
angiogenesis and intestinal stem and progenitor cell proliferation
during postnatal small intestinal development. PloS One. 2016;11:128.
53. Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, Jung MH, Ock
MS, Cha HJ. Elevated expression of thymosin β4, vascular endothelial
growth factor (VEGF), and hypoxia inducible factor (HIF)-1α in earlystage cervical cancers. Pathol Oncol Res. 2011;17:493-502.
54. Yang Z, Chen D, Zhang J, Yao D, Gao K, Wang H. The efficacy and
safety of neoadjuvant chemotherapy in the treatment of locally
Universitas Sumatera Utara
advanced cervical cancer: a randomized
Gynecologic Oncology. 2016;141:231-9.
multicenter
study.
55. Sethasathein S, Charoenkwan K, Settakorn J, Srisomboon J.
Predicting factor for positive vaginal surgical margin following radical
hysterectomy for stage IB1 carcinoma of the cervix. Asian Pac J
Cancer Prev. 2014;15:2211-5.
56. Sardi J, DiPaola GR, Cachau A, Ortiz OC, Sananes C, Giaroli A, et al.
A possible new trend in the management of the carcinoma of the
cervix uteri. Gynecology Oncology. 1986;25:139-49.
57. Eiriksson L, Miroshnichenko G, Covens A. Neoadjuvant chemotherapy
in the treatment of cervical cancer. In: Bathe OF. Neoadjuvant
chemotherapy: Current application in clinical practice. Croatia: In
Tech. 2012. p81-108.
58. Florea A-M, Busselberg D. Cisplatin as an Anti-Tumor Drug: Cellular
Mechanisms of Activity, Drug Resistance and Induced Side Effects.
Cancers. 2011;3:1351-71.
59. Furlanut M, Franceshi L. Pharmacology of ifosfamide. Oncol.
2003;65:2-6.
60. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D,
Ford R. New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). European Journal of Cancer.
2009;45:228-47.
61. Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms
of cisplatin resistance in cervical cancer. Drug Design, Development
and Therapy. 2016:10;1885–95.
62. Peng HF, Xie K, Liu XJ. Dynamic monitoring of the changes of serum
VEGF in cervical squamous cell carcinoma before and after
chemotherapy. Practical Oncol J. 2010;24:546-9.
63. Saijo Y, Furumoto H, Yoshida K, Nishimura M, Irahara M. Clinical
significance of vascular endothelial growth factor expression and
microvessel density in invasive cervical cancer. J Med Investigation.
2015;62:154-60.
Universitas Sumatera Utara
64. National Cancer Institute. NCI dictionary of cancer terms. DIakses
tanggal
11
Januari
2017.
Terdapat
di:
http://www.cancer.gov/publications/dictionaries/cancerterms?cdrid=653117
65. Maae E, Nielsen M, Steffensen KD, Jakobsen EH, Jakobsen A,
Sorensen FB. Estimation of immunohistochemical expression of
VEGF in ductal carcinomas of the breast. J Histochemist cytochemist.
2011;59:750-60.
66. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Takizawa T,
Sunamori M, et al. Sex steroid hormone receptors in human thymoma.
J Clinic Endocrinol Metabolism. 2003;88(5):2309-17.
67. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J,
Skubitz APN, Metzger GJ, Schmechel SC. Quantitative comparison of
immunohistochemical staining measured by digital image analysis
versus pathologist visual scoring. Diagnos Pathol. 2012;7:1-10.
68. Qureshi A, Pervez S. Allred scoring for ER reporting and it’s impact in
clearly distinguishing ER negative from ER positive breast cancers. J
Pak Med Assoc. 2010;60:350-3.
69. Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. A
robust automated measure of average antibody staining in
immunohistochemistry images. J Histochemist Cytochemist.
2010;58:95-107.
70. Harvey JM, Remmele W, Goldhirsch A, Wolff AX. IVD certified breast
cancer panel. Immunohistology Breast Pathology. 2013. p1-2.
Available from : http://www.zytomed-systems.com/downloads/productflyer/immunohistology/262-ivd-certified-breast-cancer-panel/file.html.
[Accessed 11st January 2017]
71. Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP,
Prasad V, Hommann M. Comparing of IRS and Her2 as
immunohistochemical scoring schemes in gastroenteropancreatic
neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187-94.
72. Fedchenko N, Reifenrath J. Different approaches for interpretation and
reporting of immunohistochemistry analysis results in the bone tissue
Universitas Sumatera Utara
– a review. Fedchenko and Reifenrath Diagnostic Pathology.
2014;9:1-12.
73. Westin MCA, Rabelo-Santos SH, Angelo-Andrade LAL, Derchain S,
Pinto GA, Morais S, Filho PL, Zeferino LC. Expression of VEGF-A in
intraepithelial and invasive cervical neoplasia. J Cytol Histol.
2015;22:1-5.
74. Kamus Besar Bahasa Indonesia (online) [diakses tanggal 29 Juni
2016]. Tersedia di: http://kbbi.web.id/umur
75. Qureshi R, Arora H, Rizvi MA. EMT in cervical cancer: it’s role in
tumour progression and response. Cancers Letters. 205;356:321-31.
Universitas Sumatera Utara
1. GLOBOCAN 2012 (IARC), Cervical Cancer, Estimated Incidence,
mortality and prevalence Worldwide in 2012. Section of Cancer
surveillance. 2012. [Diakses tanggal 21 Desember 2016]. Tersedia di:
http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp.
2. World Health Organization (WHO). Comprehensive cervical cancer
prevention and control: a healthier future for girls and women. WHO
guidance note. 2013. Geneva: WHO Press. [Diakses tanggal 21
Desember
2016].
Tersedia
di:
http://www.who.int/immunization/hpv/learn/comprehensive_cervical_c
ancer_who_2013.pdf
3. Information Centre on HPV and Cancer (ICO-HPV Information Centre).
Human Papillomavirus and Related Diseases in Indonesia. Summary
Report. December 2016. [Diakses tanggal 24 Desember 2016].
Tersedia di http://www.hpvcentre.net/statistics/reports/XWX.pdf
4. Kementerian Kesehatan Republik Indonesia (RI). Situasi penyakit
kanker. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan
Republik Indonesia. 2015. [Diakses tanggal 24 Desember 2016].
Tersedia
di:
http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodat
in-kanker.pdf
Universitas Sumatera Utara
5. Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C.
Cervical cancer: ESMO clinical practice guidelines for diagnosis,
treatment, and follow-up. Ann Oncol. 2012;23:vii27-32.
6. Mabuchi S, Kawano M, Sasano T, Kuroda H. Management of earlystage and locally advanced cervical cancer. In: Shoupe D. Handbook
of gynecology. Switzerland:Springer. 2016. p1-9.
7. Lee S-J, Kim J-H, Yoon J-H, Lee K-H, Park D-C, Kim C-J.
Neoadjuvant Chemotherapy for Cervical Cancer: Rationale and
Evolving Data. 2013. [Diakses tanggal 20 Januari 2017]. Tersedia di:
http://www.intechopen.com/books/neoadjuvant-chemotherapyincreasing-relevance-in-cancer-management/neoadjuvantchemotherapy-for-cervical-cancer-rationale-and-evolving-data
8. Bradbury M, Founta C, Taylor W, Kucukmetin A, Naik Raj, Ang C.
Pathological risk factors and outcomes in women with stage IB2
cervical cancer treated with primary radical surgery versus
chemoradiotherapy. Int J Gynecol Cancer. 2015;25:1476-83.
9. Wang H, Zhu L, Lu W, Xu H, Yu Y,Yang Y. Clinicopathological risk
factors for recurrence after neoadjuvant chemotherapy and radical
hysterectomy in cervical cancer. World Journal of Surgical Oncology.
2013;11:301
10. McCann GA, Taege SK, Boutsicaris CE, Philips GS, Eisenhauer EL,
Fowler JM, O’Malley DM, et al. The impact of close surgical margins
after radical hysterectomy for ealy-stage cervical cancer. Gynecol
Oncol. 2013;128:44-8.
11. Moore DH. Review: Neoadjuvant chemotherapy for cervical cancer.
Expert Opin. Pharmacother. 2003;4:859-67.
12. Robova H, Rob L, Halas MJ, Pluta M, Skapa P, Strnad P, et al. Highdose density neoadjuvant chemotherapy in bulky IB cervical cancer.
Gynecologic Oncology. 2013;128:49–53.
13. Friedlander M, Kaye SB, Sullivan A, Atkinson K, Elliott P, Coppleson
M. Cervical carcinoma: a drug-responsive tumor-experience with
combined cisplatin, vinblastine, and bleomycin therapy.Gynecol Oncol.
1983;16:275-81.
Universitas Sumatera Utara
14. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant
chemotherapy plus surgery versus surgery for cervical cancer.
Cochrane Collab. 2010;1:1-25.
15. Wang Y, Wang G, Wei L-H, Wang J-L, Wang S-J, Li X-P. Neoadjuvant
chemotherapy for locally advanced cervical cancer reduces surgical
risks and lymph-vascular space involvement. Chin J Cancer. 2011;30:
645-52
16. Dasari SM, Tchounwou PB. Cisplatin in cancer therapy:molecular
mechanisms of action. Eur J Pharmacol. 2014;0:364-78.
17. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of
resistance. Oncogene. 2003:22;7265-79.
18. Page R, Takimoto. Principles of chemotherapy. In: Padzur R, Coia LR,
Hoskins WJ, Wagman LD. Cancer management: A multidisciplinary
approach. Medical, surgical, and radiation Oncology. 7th eds. New
York: The Oncology Group. 2003. p21-37.
19. Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, Lee JW, et al.
Prognostic significance of VEGF expression in patients with bulky
cervical carcinoma undergoing
20. Ye Q, Yuan HX, Chen HL. Responsiveness of neoadjuvant
chemotherapy before surgery predicts favorable prognosis for cervical
cancer patients: A meta-analysis. J Cancer Res Clin Oncol.
2013;139:1887-98.
21. Ramez N, Eskander, Tawari KS. Targeting angiogenesis in advanced
cervical cancer. Ther Adv Med Oncol. 2014;6:280-92.
22. Sakurai T, Kudo M. Signaling
angiogenesis. Oncol. 2011;81:24-9.
pathways
governing
tumor
23. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell
survival functions of vascular endothelial growth factor (VEGF). J Cell
Mol Med. 2005;9:777-94.
24. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E,
Spandidos DA. VEGF, FGF, TGFB1, and TGFBR1 mRNA expression
levels correlate with the malignant transformation of the uterine cervix.
Cancer Letters. 2005;221:105-18.
Universitas Sumatera Utara
25. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peter
WA, et al. Markers of angiogenesis in high-risk, early stage cervical
cancer: A gynecologic oncology group study. Gynecol Oncol.
2009;112:583-9.
26. Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in
recurrent cervical cancer. Oncology Letters. 2010;1:3-11.
27. European Society for Medical Oncology (ESMO). Cervical cancer.
2012.[Diakses tanggal 21 Desember 2016]. Tersedia di:
https://www.esmo.org/content/download/6675/115556/file/ENCervical-Cancer-Guide-for-Patients.pdf.
28. Morshed K, Gruszka DP, Szymanski M, Dacewicz MP. Human
papillomavirus (HPV)- Structure, epidemiology and pathogenesis.
Otolaryngol Pol. 2014;150:1-7.
29. Vet JNI, de Boer MA, van den Akker BEWM, Siregar B, Lisnawati,
Budiningsih S, et al. Prevalence of human papillomavirus in Indonesia:
a population-based study in three regions. British Journal of Cancer.
2008;99:214-8
30. Domingo EJ, Noviani R, Rushdan M, Ngelangel CA, Limpaphayom
KK, Thuan TV, Louie KS, Quinn MA. Epidemiology and prevention of
cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and
Vietnam. Vaccine. 2008;26S:M71-9.
31. Rasjidi I. Epidemiologi kanker serviks. Indonesian Journal of Cancer.
2009;3:104-6.
32. Shield TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG.
A case-control study of risk factors for invasive cervical cancer among
U.S. women exposed to oncogenic types of human Papillomavirus.
Cancer Epidemol Biomarkers Prev. 2004;13:1574-80.
33. Hinkula M, Pukkala E, Kyyronen P, Laukkanen P, Koskela P,
Paavonen J. A population-based study on the risk of cervical cancer
and cervical intraepithelial neoplasia among grand multiparous women
in Finland. British Journal of Cancer. 2004;90:1025-9.
Universitas Sumatera Utara
34. Schiffman M, Wentzensen N. Human papillomavirus (HPV) infection
and the multi-stage carcinogenesis of cervical cancer. Cancer
Epidemol Biomarkers Prev. 2013;22:553-60.
35. Gómez DT, Santos JL. Human papilloma virus infection and cervical
cancer: pathogenesis and epidemiology. In: Vilas AM. Communicating
Current Research and Educational Topics and Trends in Applied
Microbiology. 2007. p680-8.
36. Hoffman BL, Schorge JO, Schaffer JI, Halvorson LM, Bradshaw KD,
Cunningham FG. Cervical Cancer. Dalam: Williams Gynecology. Edisi
ke-3. New York: McGraw-Hill. 2016. h.769-92.
37. Yan M, Zhang YN, He JH, Sun JR, Sun XM. Influence of lymph
vascular space invasion on prognosis of patients with early-stage
cervical squamous cell carcinoma. Chinese J Cancer. 2010;29:42530.
38. Eurocytology. Cervical cytology (Up to date 2016). In: Pathogenesis of
cervical cancer. Diakses tanggal 20 Januari 2017. Terdapat di:
http://www.eurocytology.eu/en/course/969
39. Khan M, Diaz-Montes TP. Cervical cancer. In: Hurt KJ, Guile MW,
Bienstock JL, Fox HE, Wallach EE. The John Hopkins manual of
gynecology and obstetrics. 4th eds. Philadelphia: Lippincott Williams &
Wilkins. 2011. p541-58.
40. Wiebe E, Denny L, Thomas G. Cancer of the cervix uteri. Int J
Gynaecol Obstet. 2012;119S2:S100-9.
41. Kementerian Kesehatan. Pedoman nasional pelayanan kedokteran
(PNPK) : Kanker Serviks. Jakarta: Kementrian Kesehatan. 2015. h.165.
42. Vaupel P, Harrison L., Tumor hypoxia: causative factors,
compensatory mechanisms, and cellular response. Oncologist. 2004;
5:4-9.
43. Masoud. GN, Li. W., HIF-1α pathway: role, regulation and intervention
for cancer therapy. Acta Pharmaceutica Sinica B. 2015;5:378-89.
Universitas Sumatera Utara
44. Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, Zoratto F, Panici
PB, Tomao S. Angiogenesis and antiangiogenic agents in cervical
cancer. OncoTargets and Therapy. 2014;7:2237-48.
45. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor
(VEGFR) signaling in angiogenesis: A crucial target for anti- and proangiogenic therapies. Genes & Cancer. 2011;2:1097-105
46. Weis SM, Cheresh DA. Tumor Angiogenesis: molecular pathways and
therapeutic targets. Nature Medicine. 2011;17:1359-64.
47. Senger DR, Davis GE. Angiogenesis. Cold Spring Harb Perspect Biol.
2011;3:1-19.
48. Bowden DJ, Barett T. Angiogenesis imaging in neoplasia. Journal of
Clinical Imaging Science. 2011;1:1-7
49. Berek JS, Hacker NF. Biology and Genetics. Dalam: Gynecologic
Oncology. Edisi ke-6. Wolters Kluwer. 2015. h.15-16.
50. Bielenberg D. Angiogenesis signaling pathway. 2014. Diakses tanggal
10
Januari
2017.
Terdapat
di:
https://www.cellsignal.com/contents/science-pathway-researchangiogenesis-resources/angiogenesis-signaling-pathway/pathwaysangiogenesis
51. Ziyad S, Iruela-Arispe ML. Molecular mechanism
angiogenesis. Genes&Cancer. 2011;2:1085-96.
of
tumor
52. Schlieve CR, Mojica SG, Holoyda KA, Hou XG, Fowler KL, Grickscheit
TC. Vascular endothelial growth factor (VEGF) bioavaibility regulates
angiogenesis and intestinal stem and progenitor cell proliferation
during postnatal small intestinal development. PloS One. 2016;11:128.
53. Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, Jung MH, Ock
MS, Cha HJ. Elevated expression of thymosin β4, vascular endothelial
growth factor (VEGF), and hypoxia inducible factor (HIF)-1α in earlystage cervical cancers. Pathol Oncol Res. 2011;17:493-502.
54. Yang Z, Chen D, Zhang J, Yao D, Gao K, Wang H. The efficacy and
safety of neoadjuvant chemotherapy in the treatment of locally
Universitas Sumatera Utara
advanced cervical cancer: a randomized
Gynecologic Oncology. 2016;141:231-9.
multicenter
study.
55. Sethasathein S, Charoenkwan K, Settakorn J, Srisomboon J.
Predicting factor for positive vaginal surgical margin following radical
hysterectomy for stage IB1 carcinoma of the cervix. Asian Pac J
Cancer Prev. 2014;15:2211-5.
56. Sardi J, DiPaola GR, Cachau A, Ortiz OC, Sananes C, Giaroli A, et al.
A possible new trend in the management of the carcinoma of the
cervix uteri. Gynecology Oncology. 1986;25:139-49.
57. Eiriksson L, Miroshnichenko G, Covens A. Neoadjuvant chemotherapy
in the treatment of cervical cancer. In: Bathe OF. Neoadjuvant
chemotherapy: Current application in clinical practice. Croatia: In
Tech. 2012. p81-108.
58. Florea A-M, Busselberg D. Cisplatin as an Anti-Tumor Drug: Cellular
Mechanisms of Activity, Drug Resistance and Induced Side Effects.
Cancers. 2011;3:1351-71.
59. Furlanut M, Franceshi L. Pharmacology of ifosfamide. Oncol.
2003;65:2-6.
60. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D,
Ford R. New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). European Journal of Cancer.
2009;45:228-47.
61. Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms
of cisplatin resistance in cervical cancer. Drug Design, Development
and Therapy. 2016:10;1885–95.
62. Peng HF, Xie K, Liu XJ. Dynamic monitoring of the changes of serum
VEGF in cervical squamous cell carcinoma before and after
chemotherapy. Practical Oncol J. 2010;24:546-9.
63. Saijo Y, Furumoto H, Yoshida K, Nishimura M, Irahara M. Clinical
significance of vascular endothelial growth factor expression and
microvessel density in invasive cervical cancer. J Med Investigation.
2015;62:154-60.
Universitas Sumatera Utara
64. National Cancer Institute. NCI dictionary of cancer terms. DIakses
tanggal
11
Januari
2017.
Terdapat
di:
http://www.cancer.gov/publications/dictionaries/cancerterms?cdrid=653117
65. Maae E, Nielsen M, Steffensen KD, Jakobsen EH, Jakobsen A,
Sorensen FB. Estimation of immunohistochemical expression of
VEGF in ductal carcinomas of the breast. J Histochemist cytochemist.
2011;59:750-60.
66. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Takizawa T,
Sunamori M, et al. Sex steroid hormone receptors in human thymoma.
J Clinic Endocrinol Metabolism. 2003;88(5):2309-17.
67. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J,
Skubitz APN, Metzger GJ, Schmechel SC. Quantitative comparison of
immunohistochemical staining measured by digital image analysis
versus pathologist visual scoring. Diagnos Pathol. 2012;7:1-10.
68. Qureshi A, Pervez S. Allred scoring for ER reporting and it’s impact in
clearly distinguishing ER negative from ER positive breast cancers. J
Pak Med Assoc. 2010;60:350-3.
69. Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. A
robust automated measure of average antibody staining in
immunohistochemistry images. J Histochemist Cytochemist.
2010;58:95-107.
70. Harvey JM, Remmele W, Goldhirsch A, Wolff AX. IVD certified breast
cancer panel. Immunohistology Breast Pathology. 2013. p1-2.
Available from : http://www.zytomed-systems.com/downloads/productflyer/immunohistology/262-ivd-certified-breast-cancer-panel/file.html.
[Accessed 11st January 2017]
71. Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP,
Prasad V, Hommann M. Comparing of IRS and Her2 as
immunohistochemical scoring schemes in gastroenteropancreatic
neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187-94.
72. Fedchenko N, Reifenrath J. Different approaches for interpretation and
reporting of immunohistochemistry analysis results in the bone tissue
Universitas Sumatera Utara
– a review. Fedchenko and Reifenrath Diagnostic Pathology.
2014;9:1-12.
73. Westin MCA, Rabelo-Santos SH, Angelo-Andrade LAL, Derchain S,
Pinto GA, Morais S, Filho PL, Zeferino LC. Expression of VEGF-A in
intraepithelial and invasive cervical neoplasia. J Cytol Histol.
2015;22:1-5.
74. Kamus Besar Bahasa Indonesia (online) [diakses tanggal 29 Juni
2016]. Tersedia di: http://kbbi.web.id/umur
75. Qureshi R, Arora H, Rizvi MA. EMT in cervical cancer: it’s role in
tumour progression and response. Cancers Letters. 205;356:321-31.
Universitas Sumatera Utara